A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result
第一作者机构：[1]Canc Inst Hosp, Beijing 100730, Peoples R China[2]Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China[3]Shanghai Chest Hosp, Shanghai, Peoples R China[4]Liaoning Canc Hosp, Zhengyang 200433, Peoples R China[5]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China[6]Beijing Chest Hosp, Beijing 266003, Peoples R China[7]Qingdao Univ, Hosp 1, Qingdao, Peoples R China[8]Sichuan Canc Hosp, Chengdu, Peoples R China[9]First Hosp, Wenzhou, Peoples R China[10]Fujian Uion Hosp, Fuzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Jie H.,Xiangru Z.,Han B.,et al.A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result[J].JOURNAL OF CLINICAL ONCOLOGY.2010,28(15):doi:10.1200/jco.2010.28.15_suppl.7019.
APA：
Jie, H.,Xiangru, Z.,Han, B.,Liu, Y.,Wang, Q....&Chen, C..(2010).A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result.JOURNAL OF CLINICAL ONCOLOGY,28,(15)
MLA：
Jie, H.,et al."A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result".JOURNAL OF CLINICAL ONCOLOGY 28..15(2010)
医学